BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $100
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan Seigerman has maintained a 'Market Perform' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raised the price target from $96 to $100.
August 04, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' price target has been raised from $96 to $100 by BMO Capital, maintaining a 'Market Perform' rating.
The increase in price target by BMO Capital indicates a positive outlook for Neurocrine Biosciences. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100